CONTEXT: Autoimmune Addison's disease (AD) is the major cause of primary adrenal failure in developed nations. Autoantibodies to 21-hydroxylase (21OH-AA) are associated with increased risk of progression to AD. Highest genetic risk is associated with the Major Histocompatibility region (MHC), specifically human leukocyte antigen (HLA)-DR3 haplotypes (containing HLA-B8) and HLA-DR4. OBJECTIVE: The objective of the study was the further characterization of AD risk associated with MHC alleles. DESIGN, SETTING, AND PARTICIPANTS: MHC genotypes were determined for HLA-DRB1, DQA1, DQB1, MICA, HLA-B, and HLA-A in 168 total individuals with 21OH-AA (85 with AD at referral and 83 with positive 21OH-AA but without AD at referral). MAIN OUTCOME MEASURE(S): Genotype was evaluated in 21OH-AA-positive individuals. Outcomes were compared with general population controls and type 1 diabetes patients. RESULTS: In HLA-DR4+ individuals, HLA-B15 was found in only one of 55 (2%) with AD vs. 24 of 63 (40%) 21OH-AA-positive nonprogressors (P = 2 × 10(-7)) and 518 of 1558 (33%) HLA-DR4 patients with type 1 diabetes (P = 1 × 10(-8)). On prospective follow-up, none of the HLA-B15-positive, 21-hydroxylase-positive individuals progressed to AD vs. 25% non-HLA-B15 autoantibody-positive individuals by life table analysis (P = 0.03). Single nucleotide polymorphism analysis revealed the HLA-DR/DQ region associated with risk and HLA-B15 were separated by multiple intervening single-nucleotide polymorphism haplotypes. CONCLUSIONS: HLA-B15 is not associated with protection from 21OH-AA formation but is associated with protection from progression to AD in 21OH-AA-positive individuals. To our knowledge, this is one of the most dramatic examples of genetic disease suppression in individuals who already have developed autoantibodies and of novel dominant suppression of an autoimmune disease by a class I HLA allele.
CONTEXT: Autoimmune Addison's disease (AD) is the major cause of primary adrenal failure in developed nations. Autoantibodies to 21-hydroxylase (21OH-AA) are associated with increased risk of progression to AD. Highest genetic risk is associated with the Major Histocompatibility region (MHC), specifically human leukocyte antigen (HLA)-DR3 haplotypes (containing HLA-B8) and HLA-DR4. OBJECTIVE: The objective of the study was the further characterization of AD risk associated with MHC alleles. DESIGN, SETTING, AND PARTICIPANTS: MHC genotypes were determined for HLA-DRB1, DQA1, DQB1, MICA, HLA-B, and HLA-A in 168 total individuals with 21OH-AA (85 with AD at referral and 83 with positive 21OH-AA but without AD at referral). MAIN OUTCOME MEASURE(S): Genotype was evaluated in 21OH-AA-positive individuals. Outcomes were compared with general population controls and type 1 diabetespatients. RESULTS: In HLA-DR4+ individuals, HLA-B15 was found in only one of 55 (2%) with AD vs. 24 of 63 (40%) 21OH-AA-positive nonprogressors (P = 2 × 10(-7)) and 518 of 1558 (33%) HLA-DR4 patients with type 1 diabetes (P = 1 × 10(-8)). On prospective follow-up, none of the HLA-B15-positive, 21-hydroxylase-positive individuals progressed to AD vs. 25% non-HLA-B15 autoantibody-positive individuals by life table analysis (P = 0.03). Single nucleotide polymorphism analysis revealed the HLA-DR/DQ region associated with risk and HLA-B15 were separated by multiple intervening single-nucleotide polymorphism haplotypes. CONCLUSIONS: HLA-B15 is not associated with protection from 21OH-AA formation but is associated with protection from progression to AD in 21OH-AA-positive individuals. To our knowledge, this is one of the most dramatic examples of genetic disease suppression in individuals who already have developed autoantibodies and of novel dominant suppression of an autoimmune disease by a class I HLA allele.
Authors: Theresa A Aly; Akane Ide; Mohamed M Jahromi; Jennifer M Barker; Maria S Fernando; Sunanda R Babu; Liping Yu; Dongmei Miao; Henry A Erlich; Pamela R Fain; Katherine J Barriga; Jill M Norris; Marian J Rewers; George S Eisenbarth Journal: Proc Natl Acad Sci U S A Date: 2006-09-11 Impact factor: 11.205
Authors: G Gambelunghe; A Falorni; M Ghaderi; S Laureti; C Tortoioli; F Santeusanio; P Brunetti; C B Sanjeevi Journal: J Clin Endocrinol Metab Date: 1999-10 Impact factor: 5.958
Authors: Peter R Baker; Erin E Baschal; Pam R Fain; Taylor M Triolo; Priyaanka Nanduri; Janet C Siebert; Taylor K Armstrong; Sunanda R Babu; Marian J Rewers; Peter A Gottlieb; Jennifer M Barker; George S Eisenbarth Journal: J Clin Endocrinol Metab Date: 2010-07-14 Impact factor: 5.958
Authors: M Rewers; T L Bugawan; J M Norris; A Blair; B Beaty; M Hoffman; R S McDuffie; R F Hamman; G Klingensmith; G S Eisenbarth; H A Erlich Journal: Diabetologia Date: 1996-07 Impact factor: 10.122
Authors: K Badenhoop; P G Walfish; H Rau; S Fischer; A Nicolay; U Bogner; H Schleusener; K H Usadel Journal: J Clin Endocrinol Metab Date: 1995-07 Impact factor: 5.958
Authors: Z Gombos; R Hermann; M Kiviniemi; S Nejentsev; K Reimand; V Fadeyev; P Peterson; R Uibo; J Ilonen Journal: Eur J Endocrinol Date: 2007-12 Impact factor: 6.664
Authors: Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox Journal: PLoS Med Date: 2006-07 Impact factor: 11.069
Authors: Sergey Nejentsev; Joanna M M Howson; Neil M Walker; Jeffrey Szeszko; Sarah F Field; Helen E Stevens; Pamela Reynolds; Matthew Hardy; Erna King; Jennifer Masters; John Hulme; Lisa M Maier; Deborah Smyth; Rebecca Bailey; Jason D Cooper; Gloria Ribas; R Duncan Campbell; David G Clayton; John A Todd Journal: Nature Date: 2007-11-14 Impact factor: 49.962
Authors: Peter Baker; Pam Fain; Heinrich Kahles; Liping Yu; John Hutton; Janet Wenzlau; Marian Rewers; Klaus Badenhoop; George Eisenbarth Journal: J Clin Endocrinol Metab Date: 2012-06-20 Impact factor: 5.958
Authors: Peter R Baker; Priyaanka Nanduri; Peter A Gottlieb; Liping Yu; Georgeanna J Klingensmith; George S Eisenbarth; Jennifer M Barker Journal: Clin Endocrinol (Oxf) Date: 2012-05 Impact factor: 3.478
Authors: Alisdair M Boag; Michael R Christie; Kerry A McLaughlin; Harriet M Syme; Peter Graham; Brian Catchpole Journal: PLoS One Date: 2015-11-30 Impact factor: 3.240